Related Experiment Video

Updated: Aug 29, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Novel agents for cutaneous T-cell lymphoma

Timothy M Kuzel1, Richard Junghans, Francine M Foss

  • 1Division of Hematology/Oncology, The Feinberg School of Medicine, and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 675 North St. Clair, Suite 21-100, Chicago, IL 60611, USA.

Hematology/Oncology Clinics of North America
|January 9, 2004
PubMed

Insights

Novel therapies show promise for treating advanced or refractory cutaneous T-cell lymphoma (CTCL). This article explores the implementation of these new agents in clinical settings for CTCL patients.

Area of Science:

  • Oncology
  • Hematology
  • Dermatology

Background:

  • Hematologic malignancies encompass a range of blood cancers.
  • Cutaneous T-cell lymphoma (CTCL) is a type of non-Hodgkin lymphoma affecting the skin.
  • Advanced or refractory CTCL presents significant treatment challenges.

Purpose of the Study:

  • To review emerging novel therapies for hematologic malignancies.
  • To discuss the potential application of these therapies in treating advanced or refractory cutaneous T-cell lymphoma.
  • To provide insights into the clinical implementation of new treatment strategies for CTCL.

Main Methods:

  • Review of recent scientific literature.
  • Analysis of in vitro and early clinical trial data for novel therapeutic agents.
  • Discussion of clinical implementation strategies for advanced or refractory CTCL.

Main Results:

  • Several novel therapeutic agents demonstrate in vitro activity against T-cell lymphomas.
  • Early clinical trials indicate promising results for some new agents.
  • These novel therapies offer potential new treatment avenues for CTCL.

Conclusions:

  • Emerging therapies hold significant potential for treating advanced or refractory cutaneous T-cell lymphoma.
  • Careful consideration of implementation strategies is crucial for optimal patient outcomes.
  • Further clinical research is warranted to fully establish the role of these novel agents in CTCL treatment.

More Related Videos

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy06:51

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.